Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

This publication has 30 references indexed in Scilit:

• Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
  PLoS Medicine, 2007
• Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
  Journal of Clinical Investigation, 2007
• Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide
  Clinical Pharmacology & Therapeutics, 2007
• Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow
  Molecular Therapy, 2007
• Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof-of-Concept and Future Directions
  Cancer Research, 2007
• Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver
  Human Gene Therapy, 2006
• Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF
  Molecular Therapy, 2006
• Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
  Proceedings of the National Academy of Sciences, 2006
• Viruses with deletions in antiapoptotic genes as potential oncolytic agents
  Oncogene, 2005
• Immune Response to Poxvirus Infections in Various Animals
  Critical Reviews in Microbiology, 2002